Bristol-Myers Squibb (BMY) Stock Outlook 2026: IRA Pricing, M&A Integration ROIC, and the Dividend
BMY 2026 deep-dive: Eliquis IRA Medicare pricing impact, Karuna/Cobenfy commercial ramp, RayzeBio radiopharma bet, Opdivo franchise against Keytruda, Mirati KRAS position, dividend sustainability with heavy M&A debt, and patent cliff math. Written for US and global investors.
BMY Bristol-Myers Squibb US Stocks
